Navigation Links
Senhwa Biosciences Raises $17M Series B
Date:12/12/2013

SAN DIEGO and NEW TAIPEI CITY, Taiwan, Dec. 12, 2013 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today. The Taiwan and San Diego, CA based company closed the round with participation from existing and new investors including H&Q Asia Pacific, Morningside and China Investment & Development Co., Ltd. Proceeds from the financing will be used to support the continuing development of its first-in-class anticancer agents CX-5461 and CX-4945 and take them through clinical proof-of-concept studies.

(Photo: http://photos.prnewswire.com/prnh/20131212/MN31456)

"Senhwa has made tremendous strides since its inception just one year ago. This round of funding will allow us to continue to advance and keeps us on course to open two new US-based Phase I and Phase II clinical trials during 2014," said Dr. Tai-Sen Soong, President of Senhwa Biosciences. "The level of commitment from new and existing investors reflects the quality of our assets, the confidence our investors have in our management team and it accelerates the development of Senhwa into a fully-fledged clinical development company."

Senhwa's lead anticancer compound for treating hematological malignancies is CX-5461, a p53 activating, Pol I inhibitor, currently in a Phase I clinical trial at the Peter MacCallum Cancer Centre in Melbourne, Australia. CX-5461 has a unique mechanism of action that enables selective activation of p53 in tumor cells but not in normal healthy ones, destroying malignant tissue while sparing the patient from the serious side effects associated with cancer therapi
'/>"/>

SOURCE Senhwa Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... 2012 Pinnacle Biologics is pleased to announce the appointment ... as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN ... Ethyol is a cytoprotective agent indicated to reduce the ... radiation treatment for head and neck cancer and to ...
... Mass., April 18, 2012  Researchers in the Program in Cellular ... the Immune Disease Institute (PCMM/IDI) have developed a ... to using RNA-based gene silencing technologies to treat cancer: Making ... there. Judy Lieberman , PhD, of ...
Cached Medicine Technology:Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries 2Packaging therapeutic RNAs for targeted treatment of breast cancer 2Packaging therapeutic RNAs for targeted treatment of breast cancer 3Packaging therapeutic RNAs for targeted treatment of breast cancer 4
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the table with ... the site has provided its faithful users with everything it ... It uniquely combines the benefits of platforms like Craigslist, Ebay ... masses. Assuring the potent herb’s followers it’s well on ... , Shane Chattin, Owner of Cannabis Classifieds said ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
Breaking Medicine News(10 mins):Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... June 2 The International Rett Syndrome,Foundation announced ... as Chief Scientific Officer, beginning July 1. Dr. ... network of Rett,Clinics, a series of clinics throughout ... In addition, Dr. Horton will,assist the IRSF Board ...
... FDA has said evidence of drug,s effectiveness lacking , , MONDAY, ... people with Parkinson,s disease combat the tics, spasms and tremors ... study suggests. , Istradfeylline works by helping nerve and ... that leads to Parkinson,s. A study of 395 Parkinson,s patients ...
... for Bad Bugs , A team of Burnham investigators ... to generate chemical inhibitors of human proteins that are hijacked ... provide a new strategy for treating infectious diseases. Because these ... targets, the hope is that resistant forms will not emerge ...
... Center, representatives available at the ASHP 2008 Summer Meeting and ... ... MOUNTAIN VIEW, Calif. and KNOXVILLE, Tenn., June 2, Omnicell, Inc., ... acute healthcare facilities, and the University of,Tennessee Medical Center today ...
... growing ... company in Alberta, CALGARY, June ... leader in the rapidly growing market for,digital radiography, today announced that ... 20th annual PROFIT 100 by PROFIT,Magazine., PROFIT Magazine, which provides ...
... & Science University Cancer Institute researchers have found that a ... the body,s own immune system to fight prostate cancer. The ... a serious type of prostate cancer one where the ... in some cases, also to chemotherapy. , Darryl Pape ...
Cached Medicine News:Health News:The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer 2Health News:Drug May Cut Tremors Associated With Parkinson's 2Health News:Recent developments at Burnham Institute 2Health News:University of Tennessee Medical Center Initiates Patient-Specific Medication Management With SinglePointe(TM) Solution From Omnicell 2Health News:University of Tennessee Medical Center Initiates Patient-Specific Medication Management With SinglePointe(TM) Solution From Omnicell 3Health News:IDC ranked no. 6 of Canada's 100 fastest growing companies by PROFIT Magazine 2Health News:IDC ranked no. 6 of Canada's 100 fastest growing companies by PROFIT Magazine 3Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 2Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: